Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
Executive Summary
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
You may also be interested in...
Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.
Three Not A Magic Number For Mayne With Another NuvaRing CRL
Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.
Alvotech Sees AbbVie’s Humira Trade Secrets Case Thrown Out In US
One part of a multi-pronged attack launched by AbbVie against Alvotech over the company’s proposed Humira (adalimumab) biosimilar has fallen, with a US district court stating that AbbVie’s US trade secrets lawsuit should be dismissed because it lacks a form of jurisdiction.